Ethnopharmacological perspectives of glucokinase activators in the treatment of diabetes mellitus

2021 ◽  
pp. 1-15
Author(s):  
Sachin Sharma ◽  
Karan Wadhwa ◽  
Manjusha Choudhary ◽  
Vikas Budhwar
1999 ◽  
Vol 138 (4) ◽  
pp. s334-s337 ◽  
Author(s):  
S RAO ◽  
A BETHEL ◽  
M FEINGLOS

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2293-PUB ◽  
Author(s):  
VEERANNA KARADI ◽  
DILIP PAWAR ◽  
SARAH JABEEN ◽  
SANDEEP S. ◽  
SAPTARSHI BOSE ◽  
...  

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 1198-1201
Author(s):  
Syed Yasir Afaque

In December 2019, a unique coronavirus infection, SARS-CoV-2, was first identified in the province of Wuhan in China. Since then, it spread rapidly all over the world and has been responsible for a large number of morbidity and mortality among humans. According to a latest study, Diabetes mellitus, heart diseases, Hypertension etc. are being considered important risk factors for the development of this infection and is also associated with unfavorable outcomes in these patients. There is little evidence concerning the trail back of these patients possibly because of a small number of participants and people who experienced primary composite outcomes (such as admission in the ICU, usage of machine-driven ventilation or even fatality of these patients). Until now, there are no academic findings that have proven independent prognostic value of diabetes on death in the novel Coronavirus patients. However, there are several conjectures linking Diabetes with the impact as well as progression of COVID-19 in these patients. The aim of this review is to acknowledge about the association amongst Diabetes and the novel Coronavirus and the result of the infection in such patients.


2019 ◽  
Vol 30 (4) ◽  
pp. 477-485
Author(s):  
R Balongo García ◽  
D Bejarano Gómez-Serna ◽  
A de la Rosa Báez ◽  
D Molina García ◽  
B García del Pino ◽  
...  

Resumen La diabetes mellitus tipo II (DM2) es una enfermedad crónica, progresiva e incurable, que ocasiona una reducción de la esperanza y de la calidad de vida. Se está produciendo un incremento epidémico global de la misma asociada a la obesidad, y a largo plazo se convertirá en la mayor carga sobre los sistemas sanitarios. Aunque existe un tratamiento efectivo para la diabetes, muchos de los pacientes sólo con el tratamiento médico no consiguen los objetivos terapéuticos mínimos para el control del riesgo microvascular. Las técnicas quirúrgicas para la obesidad mórbida han demostrado que pueden controlar la hiperglucemia, y existe consenso para su uso como forma de tratamiento para algunos pacientes desde 2015. Dado que los objetivos, el tipo de respuesta y los criterios de efectividad no están relacionados directamente con el sobrepeso, estamos ante un nuevo paradigma, definido por el término cirugía metabólica.


Author(s):  
Aleksandra Baska ◽  
Kamil Leis ◽  
Przemysław Gałązka

: Berberine is an alkaloid found in plants. It has e.g. neuroprotective, anti-inflammatory and hypolipidemic activity. The research proves that it also strongly impacts the carbohydrate metabolism. The compound also protects pancreatic βcells and increases sensitivity to insulin in peripheral tissues via the induction of GLUT-1, GLUT-4 and insulin type 1 (Ins1) receptors activity. It also stimulates glycolysis and leads to a decrease in insulin resistance by macrophages polarization, lipolytic processes induction and energy expenditure enhancement (by reducing body mass and limiting insulin resistance caused by obesity). In liver berberine inhibits FOX01, SREBP1 and ChREBP pathways, and HNF-4α (hepatocyte nuclear factor 4 alpha) mRNA that hinder gluconeogenesis processes. In intestines it blocks α-glucosidase contributing to glucose absorption decrease. Its interference in intestinal flora reduces levels of monosaccharides and suppresses diabetes mellitus complications development.


2021 ◽  
Vol 7 (1) ◽  
Author(s):  
P. Resmi ◽  
G. Jitha ◽  
Vishnu Murali ◽  
Anu Gopinath

Abstract Background Medicinal importance of mangrove plant Rhizophora mucronata, a red mangrove species found in the Asian countries, has long been recognised in traditional systems of medicine. The identification of its phytoconstituents can be a starting point for the drug development. The aim of the work was to extend the current knowledge of phytoconstituents from R. mucronata and to explore its pharmacological importance in the treatment of diabetes mellitus. In the present study, we analysed the chloroform extract from the bark of the mangrove plant R. mucronata for nitrogen-containing constituents using UHPLC QTOF MS profiling, and α-amylase inhibition assay was carried out. Results Four nitrogen-containing compounds were identified from the chloroform extract of the bark of R. mucronata using UHPLC QTOF MS profiling. The compounds identified were N,N′-dicyclohexyl urea, a cryptolepine derivative (C17H15N3O), an aliphatic cyclic compound with hydroxyl and amino groups (C22H43NO), and C16H19NO2 (m/z 258.1495). The anti-amylase activity, an in vitro antidiabetic bioassay, of chloroform extract showed an IC50 value of 220.09 μg/ml. Conclusions This is the first report on the identification of nitrogen-containing compounds from the chloroform extract of the bark of the R. Mucronata. One of the compounds identified was a novel cryptolepine derivative (C16H13N3O), and it falls under the rare category indoloquinoline alkaloid. The chloroform extract also showed significant activity towards α-amylase inhibition assay. Thus, the study has gone some way towards our understanding of the efficacy of bark of the R. mucronata for the treatment of diabetes mellitus and is open for further research.


Sign in / Sign up

Export Citation Format

Share Document